GlaxoSmithKline's new diabetes med faces formidable GLP-1 foes

There's a new kid on the diabetes block. GlaxoSmithKline's ($GSK) albiglutide, now dubbed Tanzeum for the U.S. market, nabbed FDA approval Tuesday. Now, the drug will go up against a triad of other GLP-1 treatments, including Novo Nordisk's ($NVO) powerhouse Victoza and AstraZeneca's ($AZN) exanatide franchise. Report

Suggested Articles

The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.

Amarin had big plans for Vascepa after a big label expansion last year, but it lost a patent fight—and now a generic has won FDA approval.

Intercept Pharmaceuticals, eager to market its potential nonalcoholic steatohepatitis medicine obeticholic acid, will have to keep waiting.